MarginsXMarginsX
Home › Markets › Health Care › BEAM

Beam Therapeutics Inc. (BEAM)

BEAM trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$20.94
-8.28% on the day
Market cap
$2.2B
Mid cap
Revenue · 2025
$139.7M
+120.0% on 2024
Net income · 2025
-$80.0M
-57.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/0001193125-26-065194-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBEAM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001745999
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$139.7M
Net income-$80.0M
Operating income-$383.7M
Net margin-57.2%
Operating margin-274.6%
Revenue growth+120.0%
Cash$294.9M
Total assets$1.5B
P/E (computed)Net income was not positive
P/S (computed)15.5×

Warning signs

Cash runway
6.6 months
$213.3M cash at September 30, 2026
Share count, 1 year
+2.0%
2025-10-28 to 2026-10-27 · +27.0% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$19.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$213.3M cash; operating cash flow -$97.2M a quarter.Report 2026-09-30
Shares outstanding103,495,644 (2026-10-27); 101,474,944 a year earlier; 81,504,057 three years earlier.Cover page 2026-10-27
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-02-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $19.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$307K-$134.4M-$110.7M$213.3M$100.4M$146.6M10-Q 2026-11-03
Q2 2026
2026-06-30
$490K-$122.7M-$66.1M$219.8M$100.3M$156.0M10-Q 2026-08-04
Q1 2026
2026-03-31
$31.7M-$94.3M-$128.5M$288.3M$100.2M$164.0M10-Q 2026-05-07
Q4 2025
2025-12-31
$114.1M$243.0M-$83.3M$294.9MNo debt tags$139.7M10-K 2026-02-24
Q3 2025
2025-09-30
$9.7M-$112.6M-$81.5M$268.0MNo debt tags$55.7M10-Q 2026-11-03
Q2 2025
2025-06-30
$8.5M-$102.1M-$76.5M$282.1MNo debt tags$60.3M10-Q 2026-08-04
Q1 2025
2025-03-31
$7.5M-$108.3M-$103.9M$527.9MNo debt tags$63.6M10-Q 2026-05-07
Q4 2024
2024-12-31
$30.1M-$90.4M-$76.4M$282.0MNo debt tags$63.5M10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-03-10
Latest annual report10-K2026-02-24
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-04-17

Source: SEC EDGAR submissions feed, 515 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.6%
1 month-6.5%
3 months-13.9%
Year to date-17.6%
1 year+5.4%
From 52-week high-39.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
REPLReplimune Group Inc.$21.41-2.19%$2.0B
BCRXBioCryst Pharmaceuticals Inc.$7.45-2.10%$1.9B
MAZEMaze Therapeutics Inc.$33.90-1.25%$1.9B
COAGHemab Therapeutics Holdings Inc.$39.05-4.42%$1.8B
RXRXRecursion Pharmaceuticals Inc.$2.90-8.79%$1.8B
WWBWindward Bio Group AG Common Shares$30.04+5.40%$1.7B
ALVOAlvotech$4.41+5.13%$1.7B
VIRVir Biotechnology Inc.$9.58-3.82%$1.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier